Allogene Therapeutics Annual Revenue, Number of Employees, Growth and Funding

Claim your profile


Total Funding:$819.8M
Lead Investor(s):Perceptive Advisors
Claim your profile

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Allogene Therapeutics's estimated annual revenue is currently $7M per year.
  • Allogene Therapeutics received $120.0M in venture funding in September 2018.
  • Allogene Therapeutics's estimated revenue per employee is $31,705
  • Allogene Therapeutics's total funding is $819.8M.

Employee Data

  • Allogene Therapeutics has 220 Employees.
  • Allogene Therapeutics grew their employee count by 47% last year.
  • Allogene Therapeutics currently has 27 job openings.

Executive Contacts

Bernie HuygheSr. Director
Houman DehghaniDirector
Shalini GidwaniVice President
Eric SchmidtCFO
Cesar SommerAssociate Director
David PolmanteerSenior Accounting Manager
Sarah HonigChief Of Staff
Chrissie NeumannDirector, Clinical Data Management
Eren DemirhanDirector of Biostatistics
Jack ChenVP, Controller

Allogene Therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor T-cell (CAR T) therapy directed at blood cancers and solid tumors. Founded and led by former Kite Pharma executives who bring unrivaled clinical development acumen in cell therapy, Allogene is well-positioned to further the potential of allogeneic cell therapy for patients. Allogeneic CAR T therapies are engineered from cells of healthy donors and stored for off-the-shelf use in patients. This approach eliminates the need to create personalized therapy from a patient's own cells, simplifies manufacturing, and reduces the time patients must wait for CAR T treatment. The Allogene portfolio includes 16 pre-clinical T cell therapy assets and UCART19, an allogeneic CAR T therapy currently in Phase 1 development for the treatment of acute lymphoblastic leukemia (ALL). Through its notable partnerships, Allogene leverages pioneering technology platforms, including TALEN® gene editing technology, to progress its portfolio of immuno-oncology therapies. Allogene, with headquarters in San Francisco, California, is a Two River portfolio company formed with one of the largest Series A financings in biotechnology from an investment consortium that includes TPG, Vida Ventures, BellCo Capital, the University of California Office of the Chief Investment Officer and Pfizer, among others. For more information, please visit, follow @AllogeneTx on Twitter and LinkedIn.



Number of Employees


Revenue (est)


Current Jobs


Employee Growth %


Total Funding







NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Mission Bio
Rigel Pharmaceu...
ProTrials Resea...
Trace Genomics
Advanced Cell D...
CellMax Life
Full Spectrum A...

Allogene Therapeutics News

09/03/2019 - Allogene Therapeutics Announces September 2019 Investor Conference Schedule

03, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (ALLO), a clinical-stage biotechnology company pioneering the development of ...

09/08/2019 - Allogene Therapeutics, Inc. (ALLO) Got Crushed -4.19% Today. Here’s Why

Allogene Therapeutics, Inc. (NASDAQ:ALLO) is a stock to watch today. At current price of $26.09, the shares have already lost -1.14 points ...

09/03/2019 - Artal Group S.A. Has $5.37 Million Position in Allogene Therapeutics Inc (NASDAQ:ALLO)

Artal Group S.A. reduced its position in shares of Allogene Therapeutics Inc (NASDAQ:ALLO) by 50.0% in the 2nd quarter, according to its most ...

Allogene Therapeutics Funding

DateAmountRoundLead InvestorsReference
2018-04-20$411.8MUndisclosedVida VenturesArticle
2018-09-07$120.0MUndisclosedPerceptive AdvisorsArticle

Allogene Therapeutics Executive Hires

2018-06-05Alison MooreChief Technical OfficerArticle
2018-06-19Eric SchmidtChief Financial OfficerArticle
2018-08-15Susie JunChief Development OfficerArticle
2018-08-29David TillettSVP/Head of QualityArticle